HNRNPA2B1 and non-small cell lung carcinoma: Recently, Jin et al. indicated that HNRNPA2B1 promoted NSCLC malignancy through facilitating cell growth and metastasis, suggesting that HNRNPA2B1 is a promising targeted biomarker for therapy of NSCLC [40].